25.84

2.36% -0.605

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $25.84, with a volume of 413.64K. It is down -2.36% in the last 24 hours and up +11.80% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Previous Close:

$26.45

Open:

$26.44

24h Volume:

413.64K

Relative Volume:

0.49

Market Cap:

$1.26B

Revenue:

$681.75M

Net Income/Loss:

$70.47M

P/E Ratio:

17.82

EPS:

1.45

Net Cash Flow:

$173.19M

1W Performance:

-4.85%

1M Performance:

+11.80%

6M Performance:

+49.45%

1Y Performance:

-5.09%

1-Day Range:

$25.59

$26.44

1-Week Range:

$25.59

$27.98

52-Week Range:

$11.16

$31.67

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1176)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

813-553-6680

Address

5401 WEST KENNEDY BOULEVARD, TAMPA, NJ

Employee

790

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	25.82	1.26B	681.75M	70.47M	173.19M	1.45
ZTS Zoetis Inc	157.46	68.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.37	47.71B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.62	46.12B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.45	18.55B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	298.87	13.40B	2.76B	1.11B	898.10M	22.77

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

09:13 AM

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - Yahoo Finance

09:13 AM

May 04, 2025

Pacira BioSciences soars 52% following InvestingPro’s October Fair Value alert By Investing.com - Investing.com

May 04, 2025

May 03, 2025

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis - GlobeNewswire

May 02, 2025

Revolutionary Gene Therapy Data: Pacira's New Approach Could Transform Knee Osteoarthritis Treatment - Stock Titan

May 02, 2025

Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67 - Defense World

May 02, 2025

May 01, 2025

Are Smart Investors Making the Right Decision? Pacira BioSciences Inc (PCRX) - Sete News

May 01, 2025

Apr 29, 2025

The Potential Rise in the Price of Pacira BioSciences Inc (PCRX) following insiders activity - knoxdaily.com

Apr 29, 2025

Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for - Nasdaq

Apr 29, 2025

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - GlobeNewswire

Apr 29, 2025

Leading Pain Management Company Pacira Sets Q1 2025 Earnings Call DateKey Details Inside - Stock Titan

Apr 29, 2025

LPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Apr 29, 2025